Deucravacitinib
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate-to-severe Plaque Psoriasis
Conditions
Moderate-to-severe Plaque Psoriasis
Trial Timeline
Aug 21, 2024 → Sep 30, 2028
NCT ID
NCT06258668About Deucravacitinib
Deucravacitinib is a pre-clinical stage product being developed by Bristol Myers Squibb for Moderate-to-severe Plaque Psoriasis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06258668. Target conditions include Moderate-to-severe Plaque Psoriasis.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06979453 | Phase 3 | Recruiting |
| NCT07256015 | Pre-clinical | Recruiting |
| NCT06869551 | Phase 3 | Recruiting |
| NCT06725264 | Phase 2 | Withdrawn |
| NCT06701513 | Pre-clinical | Recruiting |
| NCT06512337 | Pre-clinical | Recruiting |
| NCT06566768 | Phase 1 | Completed |
| NCT06258668 | Pre-clinical | Recruiting |
| NCT06476834 | Approved | Completed |
| NCT05821374 | Phase 1 | Withdrawn |
| NCT06091956 | Phase 2 | Completed |
| NCT05858645 | Approved | Recruiting |
| NCT05946941 | Phase 3 | Active |
| NCT06104644 | Pre-clinical | Active |
| NCT05701995 | Approved | Completed |
| NCT05617677 | Phase 3 | Active |
| NCT05620407 | Phase 3 | Active |
| NCT05556265 | Phase 2 | Terminated |
| NCT05478499 | Approved | Completed |
| NCT04908202 | Phase 3 | Active |
Competing Products
13 competing products in Moderate-to-severe Plaque Psoriasis